MammaPrint Value for Pre-menopausal Breast Cancer Patients

N/AActive Not RecruitingNCT05474391

Fudan University200 enrolled

Overview

Nearly 200 cases are to be enrolled. The information of patient age, histologic grade, tumor size, ER and PR status, Ki-67 index, surgery mode should be provided. The adjuvant therapy regime (chemotherapy: none, TC\*4, TC\*6 or EC-T; endocrine therapy: TAM, OFS+TAM, OFS+AI) will be compared before and after MammaPrint testing. About 20 clinical staffs are enrolled to participate in this survey for the clinical decision making. Each case could be chosen five times at random.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. pre-menopausal breast cancer patients aged less than 50 years old. 2. Pathology confirmed invasive dutal carcinoma or invasive lobular carcinoma. 3. receiving breast conserving surgery or mastectomy with/without reconstruction; sentinel lymph node biopsy or axillary lymph node dissection. 4. TNM staging: T1b-T2N0-1M0. 5. molecular subtype: ER positive/HER2 negative. 6. MammaPrint testing before initiation of adjuvant therapy. Exclusion Criteria: 1. Incomplete medical history. 2. Pregnancy or lactation. 3. Contradiction of chemotherapy or ovarian function suppression.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Treatment decision survey

Treatment decision change after MammaPrint testing

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.